Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines

Elias,Silvia  Taveira; Borges,Gabriel  Alvares; Rêgo,Daniela  Fortunato; Oliveira E Silva,Luis  Felipe; Avelino,Samuel; Nunes de Matos Neto,João; Simeoni,Luiz  Alberto; Guerra,Eliete  Neves Silva

doi:10.3892/ol.2015.3458

Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines

Authors:
- Silvia Taveira Elias
- Gabriel Alvares Borges
- Daniela Fortunato Rêgo
- Luis Felipe Oliveira E Silva
- Samuel Avelino
- João Nunes de Matos Neto
- Luiz Alberto Simeoni
- Eliete Neves Silva Guerra
View Affiliations

Affiliations: Faculty of Health Sciences, Campus Darcy Ribeiro, University of Brasília, Brasília, Federal District 70910‑900, Brazil, Center of High Complexity in Oncology, University Hospital of Brasília, Brasília, Federal District 70910‑900, Brazil
Published online on: July 6, 2015 https://doi.org/10.3892/ol.2015.3458
Pages: 1721-1727

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although taxels (in particular paclitaxel), cisplatin and fluorouracil (TPF) chemotherapy has been approved for use in the treatment of head and neck squamous cell carcinoma (HNSCC), little is known with regard to the cellular mechanisms of this novel drug association. In order to investigate the reaction of cells to this novel treatment, the present study aimed to examine the cytotoxic effect of TPF in HNSCC cell lines in combination with irradiation, to analyze its effect on cell cycle progression and cell death, and to evaluate its ability to alter cell migration. An MTT assay was used to determine cell viability following TPF and cisplatin treatments in two human HNSCC cell lines (FaDu and SCC‑9) and one keratinocyte cell line (HaCaT). The concurrent use of TPF or cisplatin and irradiation was also analyzed. Flow cytometric analysis was utilized to determine the cell cycle distribution and to verify the induction of apoptosis. The capacity of the drugs to alter oral cancer cell migration was also evaluated using a Transwell migration assay. The results indicated that TPF and cisplatin were cytotoxic to all cell lines, and enhanced the effects of ionizing radiation. FaDu cells were significantly more sensitive to the two treatments, and TPF was more cytotoxic than cisplatin for all cells. Flow cytometric analysis revealed that TPF increased the number of cells in G0/G1 phase in the SCC‑9 cell line, and indicated apoptotic cell death. The results of the Transwell assay demonstrated that TPF inhibited migration in oral carcinoma cell lines. The results of the present study indicated that TPF functions in oral carcinoma cell lines through the enhancement of ionizing radiation effects, inducing cell cycle arrest at G0/G1 and apoptosis, in addition to inhibiting migration.

View Figures

View References

1	Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009. View Article : Google Scholar : PubMed/NCBI
2	Instituto Nacional de. Câncer, . Brazilian cancer incidence. https://www.inca.gov.br/estimativa/2014Accessed. February 15–2014
3	Warnakulasuriya S: Causes of oral cancer - an appraisal of controversies. Br Dent J. 207:471–475. 2009. View Article : Google Scholar : PubMed/NCBI
4	Thavaraj S, Stokes A, Guerra E, Bible J, Halligan E, Long A, Okpokam A, Sloan P, Odell E and Robinson M: Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol. 64:308–312. 2011. View Article : Google Scholar : PubMed/NCBI
5	Shah JP and Gil Z: Current concepts in management of oral cancer - surgery. Oral Oncol. 45:394–401. 2009. View Article : Google Scholar : PubMed/NCBI
6	Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM and Garden AS: Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 75:725–733. 2009. View Article : Google Scholar : PubMed/NCBI
7	Zhang N, Erjala K, Kulmala J, Qiu X, Sundvall M, Elenius K and Grénman R: Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol. 92:388–392. 2009. View Article : Google Scholar : PubMed/NCBI
8	Posner MR, Hershock DM, Blajman CR, et al TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
9	Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE and Katsilieris I: Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: Final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol. 42:675–684. 2006. View Article : Google Scholar : PubMed/NCBI
10	Vermorken JB, Remenar E, van Herpen C, et al EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
11	(NCI/NIH) NCI, . FDA approval for docetaxel. simplewww.cancer.gov/cancertopics/druginfo/fda-docetaxelAccessed. February 15–2014
12	Lim YC, Oh SY, Cha YY, Kim SH, Jin X and Kim H: Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol. 47:83–91. 2011. View Article : Google Scholar : PubMed/NCBI
13	Belcher R, Hayes K, Fedewa S and Chen AY: Current treatment of head and neck squamous cell cancer. J Surg Oncol. 110:551–574. 2014. View Article : Google Scholar : PubMed/NCBI
14	Florea AM and Büsselberg D: Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers Basel. 3:1351–1371. 2011. View Article : Google Scholar : PubMed/NCBI
15	Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zheng XK, Chen LH, Wang WJ, Ye F, Liu JB, Li QS and Sun HW: Impact of prolonged fraction delivery times simulating IMRT on cultured nasopharyngeal carcinoma cell killing. Int J Radiat Oncol Biol Phys. 78:1541–1547. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zhong LP, Zhu DW, William WN Jr, et al: Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 12:1112–1121. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
19	Bozec A, Sudaka A, Etienne-Grimaldi MC, Brunstein MC, Fischel JL and Milano G: Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model. Oral Oncol. 47:940–945. 2011. View Article : Google Scholar : PubMed/NCBI
20	Scanlon CS, Van Tubergen EA, Inglehart RC and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
21	Smith A, Teknos TN and Pan Q: Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 49:287–292. 2013. View Article : Google Scholar : PubMed/NCBI